New drug combo aims to tackle deadly pancreatic cancer
NCT ID NCT07665684
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called samuraciclib added to standard chemotherapy for people with a specific type of advanced pancreatic cancer (basal-like). The goal is to find the safest dose and see if the combination helps shrink tumors or slow the cancer. About 67 adults with newly diagnosed metastatic pancreatic cancer will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- samuraciclib (a CDK7 inhibitor) combined with gemcitabine and nab-paclitaxel chemotherapy
- What this could lead to
- If successful, this could lead to a new treatment option for a hard-to-treat type of pancreatic cancer, potentially improving how long patients live or how well they respond to therapy.
- What could go wrong
- This is an early-phase trial with only 67 participants, so results may not apply to all patients. The drug combination may cause severe side effects or fail to improve outcomes compared to standard chemo alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOSQUAMOUS CARCINOMA OF THE PANCREAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2C4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Virus therapy aims to boost chemo in tough pancreatic cancer
- Scientists hunt for weaknesses in pancreatic Cancer's fuel system
- New hope for hard-to-treat pancreatic cancer: targeted drug combo enters phase 3 trial
- Last-Resort drug access opens for advanced pancreatic cancer patients
- New combo therapy targets Hard-to-Treat cancers